VasoDynamics strengthens the Board with key appointments

Building a strong Board of industry experts to enable progress to market access

• Dr Laurence Reilly, Non-executive Chair

• Mr Darren Fergus, Non-executive Director

• Ms Wills (Alexandra) Hughes-Wilson, Non-executive Director

• Mrs Hilary Birrell, Executive Director

2nd Sep 2024 – VasoDynamics Ltd, the pharmaceutical company developing preventive therapies for common complications in cancer treatment, today announces key appointments to strengthen the Board.

Ningfeng Fiona Li, CEO of VasoDynamics, said:

“With our platform products and clinical programmes progressing rapidly, supported by the successful completion of NG11-2 Phase-Ib trial for the prevention of severe mouth ulceration in the patients with head and neck cancers undergoing chemoradiotherapy/radiotherapy, it is vital that we strengthen the Board with the necessary industry experience to lead the company into the next stage of global clinical development and market access. We are delighted to announce the appointments of Dr Laurence Reilly, Mr Darren Fergus, Mrs Alexandra Hughes-Wilson and Mrs Hilary Birrell as new Board members, with Dr Laurence Reilly as the Chairperson, who will bring invaluable experience to the Board leadership and governance as we enter the next value inflection phase of clinical and commercialisation development.”

Dr Laurence Reilly, Non-executive Chairman

Dr Reilly is a medical doctor by training and serves as Senior independent Non-Executive Director for Immupharma, an AIM-listed specialty biopharma company based in London. Dr Reilly also serves as Vice President, Head of Clinical, Research & Investments working with Royalty Pharma, a New York based life science investment company focussing on the acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry. Dr Reilly previously served as Chief Medical Officer at Cellectar Biosciences, New Jersey, a late-stage oncology biotech company, and as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor. Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Mr Darren Fergus, NED

With three decades of experience across big Pharma, biotech, and medtech, Darren Fergus has a deep understanding of healthcare. For more than a decade he has led organisations in Europe, the UK, and Ireland. Darren is CEO and co-founder of Profionics, President of Tweidpharma, Non-Executive Director of VasoDynamics, and Lay Trustee of the Intensive Care Society.

Ms Wills (Alexandra) Hughes-Wilson, NED

Ms Hughes-Wilson, executive at Mereo BioPharma, has a background in law, with over 20 years’ experience in the biopharma industry with increasing responsibility and leadership roles in US and European-based publicly traded biotechnology companies across a broad range of therapeutic areas, including rare diseases, oncology and other speciality pharma. The main focus of her recent operational roles includes defining pathways to market and providing strategic input into development programmes as well as product launch preparation and commercial delivery.

Mrs Hilary Birrell, Executive Director and Head of Clinical Operations

Mrs Birrell is a biochemist and clinical trial specialist with over 30 years’ experience in multiple indications across Phases I-IV of drug development. Her early career in AstraZeneca was followed by 20 years of consultancy experience as the owner/Director of Carnegie Clinical Research Ltd, a Clinical Trial Management CRO, since 2010. She has been an executive team member of VasoDynamics since 2021 and has deep understanding of the company’s development scope and operational hurdles.

Dr Reilly, as the chairman of the Board, said:

“I am delighted to have joined VasoDynamics at such an exciting time of the company’s development, with several programmes entering late-stage and clinical development phases. I am looking forward to working with the Board and the executive team as we accelerate the company’s clinical trial programmes progress and potential commercial opportunities.”

Media:

Dr Ningfeng Fiona Li, CEO +44 7969132263

fiona.li@vasonewsitedev.wpengine.com

Gary Bower, COO +44 7960388412

gary.bower@vasonewsitedev.wpengine.com

Notes to Editors:

About VasoDynamics

VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.